Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. demonstrated a substantial revenue increase, reporting Q3 FY25 revenues of $6.8 million, which represents a 76% year-over-year growth, driven primarily by the integration of its new SCN model. This innovative approach not only accelerated patient adoption and case starts but also significantly enhanced service revenue, which more than doubled to $4.6 million, indicating strong market traction for its sleep-disordered breathing solutions. Additionally, the positive clinical outcomes reported, with a significant percentage of patients experiencing improvement, alongside the projected growth in the Asia Pacific market, underscores the company's potential for continued revenue expansion in both North America and international markets.

Vivos Therapeutics Inc. has reported a year-over-year revenue decline of 9% for the first half of 2025, totaling $6.8 million, as it transitions from its legacy business model to new sleep center operations, with Q2 revenues of $3.8 million falling short of estimates. The company also experienced a drop in gross margins to 55% during the same quarter due to discounting and a changing product mix, further highlighting challenges in its financial position. Additionally, the business faces significant risks, including competition, regulatory hurdles, and ongoing operating losses, which raise concerns about its ability to secure capital and achieve sustainable profitability in the future.